Search

Lauren Gail Otsuki

from San Diego, CA
Age ~71
Get Report
Also known as:
Lauren G Otsuki, Lauren Gail Ciski, Lauren G O Blake, Lauren G Blake, Lauren O Blake, Ki Lauren Cis, Blake Otsuki
Phone and address:
16749 Calle Hermosa, San Diego, CA 92127
Related to:
Frederick L Blake, 33Christopher W Blake, 70Darren M Blake, 35Sean Blake, 30
Connected to:
Michiko Otsuki, 95Richard K Otsuki, 80Shuhei Otsuki, 52Allie Ott, 65Amber D Ott, 41Andrew Ott, 60Aneta W Ott, 86Angelique Ott, 35Bavionne Ott, 48Beau R Ott, 54

Lauren Otsuki Phones & Addresses

  • 16749 Calle Hermosa, San Diego, CA 92127
  • Haddam, CT
  • Vista, CA
  • Sanger, CA
  • Oceanside, CA

Work

Company: Oncternal therapeutics Dec 2013 Position: Founder, chief operations officer

Education

Degree: Bachelors School / High School: University of California, Davis Specialities: Biochemistry

Skills

Start Ups • Lifesciences • Entrepreneurship • Product Development • Strategic Planning • Business Development • Business Strategy • Marketing Strategy • Project Management • Research • Product Management • Medical Devices • New Business Development • Marketing • Biochemistry • Venture Capital • Pharmaceutical Industry • Microsoft Office • Biotechnology

Industries

Biotechnology

Resumes

Resumes

Lauren Otsuki Photo 1

Founder, Chief Operations Officer

View page
Location:
San Diego, CA
Industry:
Biotechnology
Work:
Oncternal Therapeutics
Founder, Chief Operations Officer
Selexagen Therapeutics Jan 2009 - 2012
Founder
Kanisa Pharmaceuticals Apr 2006 - Jun 2008
Senior Vice President Commerical Development
Novacardia Jan 2003 - Jun 2006
Founder, Vice President Business and Commercial Development
Dexcom Mar 1999 - Dec 2002
Founder, Vice President Business Development
Education:
University of California, Davis
Bachelors, Biochemistry
Skills:
Start Ups
Lifesciences
Entrepreneurship
Product Development
Strategic Planning
Business Development
Business Strategy
Marketing Strategy
Project Management
Research
Product Management
Medical Devices
New Business Development
Marketing
Biochemistry
Venture Capital
Pharmaceutical Industry
Microsoft Office
Biotechnology

Business Records

Name / Title
Company / Classification
Phones & Addresses
Lauren G. Otsuki
President
Rancho Santa Fe Youth Soccer
Membership Sport/Recreation Club
PO Box 1373, Rancho Santa Fe, CA 92067
616 Stevens Ave, Solana Beach, CA 92075
Lauren G. Otsuki
President
OPUS CONSULTING, INC
16749 Calle Hermosa, San Diego, CA 92127

Publications

Us Patents

Method Of Treatment Of Disease Using An Adenosine A1 Receptor Antagonist

View page
US Patent:
20040229901, Nov 18, 2004
Filed:
Feb 23, 2004
Appl. No.:
10/785446
Inventors:
Lauren Otsuki - San Diego CA, US
Howard Dittrich - San Diego CA, US
Kenneth Widder - Rancho Santa Fe CA, US
Roland Blantz - Del Mar CA, US
Scott Thomson - Poway CA, US
International Classification:
A61K031/4745
A61K031/4184
A61K031/401
A61K031/137
US Classification:
514/303000, 514/381000, 514/651000, 514/423000
Abstract:
Disclosed are pharmaceutical composition comprising a beta-blocker and an adenosine Areceptor antagonist (AARA), an angiotensin converting enzyme (ACE) inhibitor and an adenosine Areceptor antagonist (AARA), and an angiotensin II receptor blocker (ARB) and an adenosine Areceptor antagonist (AARA). Also disclosed are methods of treating cardiovascular disease, renal disease, alkalosis, or diabetic nephropathy comprising identifying a patient in need of such treatment, and administering a pharmaceutical composition disclosed herein to said patient.

Method Of Improved Diuresis In Individuals With Impaired Renal Function

View page
US Patent:
20050004145, Jan 6, 2005
Filed:
Apr 23, 2004
Appl. No.:
10/830617
Inventors:
Kenneth Widder - Rancho Santa Fe CA, US
Lauren Otsuki - San Diego CA, US
Howard Dittrich - San Diego CA, US
Scott Thomson - Poway CA, US
Roland Blantz - Del Mar CA, US
International Classification:
A61K031/522
A61K031/405
US Classification:
514263300
Abstract:
Disclosed is a pharmaceutical composition comprising a therapeutically effective amount of KW-3902, or a salt, ester, amide, metabolite, or prodrug thereof, and a non-adenosine modifying diuretic. Also disclosed are methods of inducing a diuretic effect in an animal comprising the step of administering a therapeutically effective amount of KW-3902, or a salt, ester, amide, metabolite, or prodrug thereof, in combination with second pharmaceutical composition capable of inducing a diuretic effect.

Method Of Treatment Of Disease Using An Adenosine A1 Receptor Antagonist And An Aldosterone Inhibitor

View page
US Patent:
20050239759, Oct 27, 2005
Filed:
Apr 14, 2005
Appl. No.:
11/107637
Inventors:
Lauren Otsuki - San Diego CA, US
Kenneth Widder - Rancho Santa Fe CA, US
Howard Dittrich - San Diego CA, US
International Classification:
A61K031/56
A61K031/4745
US Classification:
514171000, 514303000
Abstract:
Pharmaceutical compositions comprising an aldosterone inhibitor and an adenosine Areceptor antagonist (AARA) and methods of treating cardiovascular disease comprising identifying a patient in need of such treatment, and administering a pharmaceutical composition disclosed herein to said patient are disclosed.

Method Of Improved Diuresis In Individuals With Impaired Renal Function

View page
US Patent:
20060030572, Feb 9, 2006
Filed:
Oct 11, 2005
Appl. No.:
11/248479
Inventors:
Kenneth Widder - Rancho Santa Fe CA, US
Lauren Otsuki - San Diego CA, US
Howard Dittrich - San Diego CA, US
Scott Thomson - Poway CA, US
Roland Blantz - Del Mar CA, US
International Classification:
A61K 31/549
A61K 31/522
US Classification:
514263320, 514223500
Abstract:
Disclosed is a pharmaceutical composition comprising a therapeutically effective amount of KW-3902, or a salt, ester, amide, metabolite, or prodrug thereof, and a non-adenosine modifying diuretic. Also disclosed are methods of inducing a diuretic effect in an animal comprising the step of administering a therapeutically effective amount of KW-3902, or a salt, ester, amide, metabolite, or prodrug thereof, in combination with second pharmaceutical composition capable of inducing a diuretic effect.

Method Of Improved Diuresis In Individuals With Impaired Renal Function

View page
US Patent:
20060035911, Feb 16, 2006
Filed:
Oct 11, 2005
Appl. No.:
11/248905
Inventors:
Kenneth Widder - Rancho Santa Fe CA, US
Lauren Otsuki - San Diego CA, US
Howard Dittrich - San Diego CA, US
Scott Thomson - Poway CA, US
Roland Blantz - Del Mar CA, US
International Classification:
A61K 31/549
A61K 31/522
US Classification:
514263320, 514223500
Abstract:
Disclosed is a pharmaceutical composition comprising a therapeutically effective amount of KW-3902, or a salt, ester, amide, metabolite, or prodrug thereof, and a non-adenosine modifying diuretic. Also disclosed are methods of inducing a diuretic effect in an animal comprising the step of administering a therapeutically effective amount of KW-3902, or a salt, ester, amide, metabolite, or prodrug thereof, in combination with second pharmaceutical composition capable of inducing a diuretic effect.

Method Of Treatment Of Cardiac And/Or Renal Failure Using A Calcium Channel Blocker And An Angiotensin Converting Enzyme Inhibitor Or An Angiotensin Ii Receptor Blocker

View page
US Patent:
20060058355, Mar 16, 2006
Filed:
Aug 23, 2005
Appl. No.:
11/209463
Inventors:
Howard Dittrich - San Diego CA, US
Lauren Otsuki - San Diego CA, US
Kenneth Widder - Rancho Santa Fe CA, US
International Classification:
A61K 31/455
A61K 31/4439
US Classification:
514338000, 514355000
Abstract:
Disclosed is a pharmaceutical composition comprising a calcium channel blocker and an angiotensin II receptor blocker or an angiotensin converting enzyme inhibitor. Also disclosed is a method of treating cardiovascular disease or renal disease comprising identifying a patient in need of such treatment, and administering a pharmaceutical composition disclosed herein to said patient.

Method Of Treatment Of Cardiac And/Or Renal Failure Using A Calcium Channel Blocker And An Angiotensin Converting Enzyme Inhibitor Or An Angiotensin Ii Receptor Blocker

View page
US Patent:
20090118334, May 7, 2009
Filed:
Jan 9, 2009
Appl. No.:
12/351728
Inventors:
Howard C. Dittrich - San Diego CA, US
Lauren Otsuki - San Diego CA, US
Kenneth J. Widder - Rancho Sante Fe CA, US
Assignee:
Diakron Pharmaceuticals, Inc. - Roseland NJ
International Classification:
A61K 31/4439
A61K 31/44
A61P 9/00
US Classification:
514339, 514356
Abstract:
A pharmaceutical composition including a calcium channel blocker and an angiotensin II receptor blocker or an angiotensin converting enzyme inhibitor. Also disclosed is a method of treating cardiovascular disease or renal disease by identifying a patient in need of such treatment, and administering a pharmaceutical composition disclosed herein to said patient.

Method Of Treatment Of Disease Using An Adenosine A1 Receptor Antagonist And An Aldosterone Inhibitor

View page
US Patent:
20090253665, Oct 8, 2009
Filed:
Jun 16, 2009
Appl. No.:
12/485797
Inventors:
Lauren Otsuki - San Diego CA, US
Kenneth Widder - Rancho Santa Fe CA, US
Howard C. Dittrich - San Diego CA, US
International Classification:
A61K 31/585
A61K 31/522
A61P 9/00
A61P 13/12
A61P 9/04
A61P 9/12
A61P 9/10
US Classification:
514171, 514173, 51426323, 51426324
Abstract:
Pharmaceutical compositions comprising an aldosterone inhibitor and an adenosine Areceptor antagonist (AARA) and methods of treating cardiovascular disease comprising identifying a patient in need of such treatment, and administering a pharmaceutical composition disclosed herein to said patient are disclosed.
Control profile
Lauren Gail Otsuki from San Diego, CA, age ~71 Get Report